NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM was delisted on the 4th of April, 2024.
108 hedge funds and large institutions have $1.25B invested in NGM Biopharmaceuticals, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 39 increasing their positions, 18 reducing their positions, and 8 closing their positions.
263% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 8
227% more call options, than puts
Call options by funds: $1.4M | Put options by funds: $430K
117% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 18
23% more funds holding
Funds holding: 88 → 108 (+20)
11% more capital invested
Capital invested by funds: $1.12B → $1.25B (+$127M)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$77M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.6M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$11.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$10.6M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$10.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
Euclidean Capital
New York
|
-$16.5M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.42M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$1.37M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$1.19M |
| 5 |
MS
Maven Securities
St Helier,
Jersey
|
-$1.04M |
NGM Hedge Fund Activity: Q1 2021 in Review
108 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q1 2021, worth a combined $1.25B — up 11% from $1.12B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new NGM positions and 8 closed out — a net gain of 21 holders — while 39 added to existing stakes and 18 trimmed.
The largest buyer was Redmile Group, opening a new position worth an estimated $77M. The largest seller was Euclidean Capital, cutting an estimated $16.5M.
- 108 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q1 2021, up from 88 in Q4 2020.
- Funds reported $1.25B of NGM Biopharmaceuticals, Inc. Common Stock stock for Q1 2021, up 11% quarter-over-quarter.
- 29 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q1 2021 and 8 closed out, a net change of +21 holders.
- The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q1 2021 was Redmile Group, an estimated $77M added.
- The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q1 2021 was Euclidean Capital, an estimated $16.5M sold.
Based on aggregated 13F filings for Q1 2021.